

Julian Carretero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1086291/publications.pdf>

Version: 2024-02-01

64
papers

5,477
citations

87843

38
h-index

161767

54
g-index

66
all docs

66
docs citations

66
times ranked

10447
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetics and precision medicine in lung cancer. , 2022, , 109-145.		1
2	A Very Rare Variant in SREBF2, a Possible Cause of Hypercholesterolemia and Increased Glycemic Levels. Biomedicines, 2022, 10, 1178.	1.4	2
3	Srebf2 Locus Overexpression Reduces Body Weight, Total Cholesterol and Glucose Levels in Mice Fed with Two Different Diets. Nutrients, 2020, 12, 3130.	1.7	1
4	Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Cancer Research, 2020, 80, 4224-4232.	0.4	12
5	Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models. Cancers, 2020, 12, 3712.	1.7	6
6	Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS ONE, 2020, 15, e0228909.	1.1	66
7	Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.. Journal of Clinical Oncology, 2020, 38, e15042-e15042.	0.8	0
8	CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Cancer Research, 2019, 79, 4439-4452.	0.4	44
9	LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics. Analytical Chemistry, 2019, 91, 836-845.	3.2	33
10	De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. FASEB Journal, 2018, 32, 7018-7027.	0.2	33
11	PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. Genome Medicine, 2018, 10, 41.	3.6	63
12	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Journal of Thoracic Oncology, 2017, 12, 1268-1279.	0.5	152
13	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213.	3.2	66
14	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213.	3.2	66
15	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021.	7.7	108
16	Abstract 4479: Unveiling the relationship between the SWI/SNF chromatin remodeling complex and noncoding RNAs. , 2016, , .		0
17	Expression inactivation of SMARCA4 by microRNAs in lung tumors. Human Molecular Genetics, 2015, 24, 1400-1409.	1.4	26
18	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2015, 27, 149.	7.7	3

#	ARTICLE	IF	CITATIONS
19	<i>PARD3</i> Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. <i>Cancer Research</i> , 2015, 75, 1287-1297.	0.4	44
20	Intratumoral Heterogeneity in <i>EGFR</i> -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2015, 75, 4372-4383.	0.4	108
21	Abstract 3940: Inactivation of the <i>PARD3</i> gene is a recurrent event in lung squamous cell carcinomas and affects STAT3 activity and tumor invasiveness. , 2015, , .		0
22	Abstract 753: Genomic alterations of autophagy genes disrupts autophagic flux in human lung adenocarcinomas. , 2015, , .		0
23	Abstract 766: Suppression of gefitinib-induced EMT in <i>EGFR</i> mutant NSCLC preferentially selects for acquired T790M. , 2015, , .		0
24	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2014, 26, 909-922.	7.7	376
25	D-2-hydroxyglutarate produced by mutant <i>IDH2</i> causes cardiomyopathy and neurodegeneration in mice. <i>Genes and Development</i> , 2014, 28, 479-490.	2.7	70
26	β -Catenin Contributes to Lung Tumor Development Induced by <i>EGFR</i> Mutations. <i>Cancer Research</i> , 2014, 74, 5891-5902.	0.4	76
27	Abstract 968: β -catenin plays an important role in lung tumor development induced by <i>EGFR</i> mutations. , 2014, , .		0
28	Activation of the PD-1 Pathway Contributes to Immune Escape in <i>EGFR</i> -Driven Lung Tumors. <i>Cancer Discovery</i> , 2013, 3, 1355-1363.	7.7	1,073
29	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <i>LKB1</i> -Mutant Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 870-879.	7.7	127
30	Efficacy of BET Bromodomain Inhibition in <i>Kras</i> -Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6183-6192.	3.2	179
31	Abstract B290: Activation of the PD-1 pathway contributes to immune escape in <i>EGFR</i> -driven lung tumors. , 2013, , .		26
32	Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in <i>Kras</i> -Driven Murine Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e80885.	1.1	23
33	Abstract A292: Salinomycin, an anti-cancer stem cell antibiotic, overcomes acquired resistance to <i>BRAF</i> inhibitors in <i>BRAF</i> -mutant human melanoma cell lines. , 2013, , .		0
34	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4973-4985.	3.2	141
35	Novel Transcriptional Targets of the SRY-HMG Box Transcription Factor <i>SOX4</i> Link Its Expression to the Development of Small Cell Lung Cancer. <i>Cancer Research</i> , 2012, 72, 176-186.	0.4	73
36	Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response. <i>Cancer Research</i> , 2012, 72, 5921-5933.	0.4	31

#	ARTICLE	IF	CITATIONS
37	Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8699-8704.	3.3	114
38	ETS-1 Regulates Twist-1 Expression In Non-Small Cell Lung Cancer (NSCLC) Progression And Metastasis. , 2011, , .		1
39	Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors. Cancer Cell, 2010, 17, 547-559.	7.7	215
40	Increased Ets-1 Positively Correlates With Twist1 Expression In Mouse Non-small Cell Lung Cancer (NSCLC) Progression And Metastases. , 2010, , .		0
41	Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by <i>EML4-ALK</i> Fusion Oncogene. Cancer Research, 2010, 70, 9827-9836.	0.4	181
42	HIF2 α cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 2160-2170.	3.9	129
43	Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels. Nitric Oxide - Biology and Chemistry, 2008, 19, 107-114.	1.2	15
44	Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Molecular Cancer Therapeutics, 2008, 7, 3330-3342.	1.9	81
45	Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease. Clinical Cancer Research, 2007, 13, 2658-2666.	3.2	68
46	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625.	2.6	130
47	Bcl-2 and Mn-SOD Antisense Oligodeoxynucleotides and a Glutamine-enriched Diet Facilitate Elimination of Highly Resistant B16 Melanoma Cells by Tumor Necrosis Factor- α and Chemotherapy. Journal of Biological Chemistry, 2006, 281, 69-79.	1.6	40
48	Acceleration of Glutathione Efflux and Inhibition of γ -Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity. Journal of Biological Chemistry, 2005, 280, 6950-6959.	1.6	82
49	Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. Human Molecular Genetics, 2005, 14, 973-982.	1.4	55
50	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene, 2004, 23, 4037-4040.	2.6	111
51	Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene, 2004, 23, 5084-5091.	2.6	61
52	A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria?. Hepatology, 2004, 39, 570-571.	3.6	2
53	Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology, 2004, 39, 711-720.	3.6	127
54	Genetic and Epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes and Cancer, 2004, 41, 170-177.	1.5	103

#	ARTICLE	IF	CITATIONS
55	Tumor Cytotoxicity by Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 13888-13897.	1.6	44
56	Down-regulation of Glutathione and Bcl-2 Synthesis in Mouse B16 Melanoma Cells Avoids Their Survival during Interaction with the Vascular Endothelium. <i>Journal of Biological Chemistry</i> , 2003, 278, 39591-39599.	1.6	42
57	Inhibition of cancer growth by resveratrol is related to its low bioavailability. <i>Free Radical Biology and Medicine</i> , 2002, 33, 387-398.	1.3	338
58	$\hat{1}^3$ -Glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. <i>Hepatology</i> , 2002, 35, 74-81.	3.6	81
59	Glutamine potentiates TNF- $\hat{1}^{\pm}$ -induced tumor cytotoxicity. <i>Free Radical Biology and Medicine</i> , 2001, 31, 642-650.	1.3	36
60	Tumoricidal Activity of Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 25775-25782.	1.6	47
61	Possible Mechanisms for Tumour Cell Sensitivity to TNF-a and Potential Therapeutic Applications. <i>Current Pharmaceutical Biotechnology</i> , 2001, 2, 119-130.	0.9	17
62	Mitochondrial glutathione depletion by glutamine in growing tumor cells. <i>Free Radical Biology and Medicine</i> , 2000, 29, 913-923.	1.3	38
63	Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 567-574.	1.7	99
64	Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. <i>Free Radical Biology and Medicine</i> , 1999, 26, 410-418.	1.3	180